NCT02107092View on ClinicalTrials.gov

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

PHASE3CompletedINTERVENTIONAL

Enrollment

123

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

July 31, 2015

Study Completion Date

August 31, 2015

Conditions

Hyperkalemia

Interventions

DRUG

Sodium Zirconium Cyclosilicate

Oral 10g once daily with breakfast for 11 months.

Trial Locations (49)

11355

Flushing

16602

Altoona

29118

Orangeburg

29150

Sumter

30030

Decatur

31901

Columbus

32132

Edgewater

32168

New Smyrna Beach

32720

DeLand

32789

Winter Park

33014

Miami Lakes

33015

Miami

33018

Miami Lakes

33125

Miami

33462

Atlantis

33511

Brandon

33607

Tampa

33614

Tampa

34208

Bradenton

34471

Ocala

34491

Summerfield

34601

Brooksville

35768

Scottsboro

35801

Huntsville

36207

Anniston

37408

Chattanooga

48047

Chesterfield

60435

Joliet

60805

Evergreen Park

64411

Kansas City

71101

Shreveport

78229

San Antonio

85027

Phoenix

85284

Tempe

89115

Las Vegas

90022

Los Angeles

90716

Hawaiian Gardens

90723

Paramount

92505

Riverside

04210

Auburn

02903

Providence

Unknown

Gosford

Woolloongabba

Heidelberg

Melbourne

Parkville

Meyerspark

Port Elizabeth

Somerset West

All Listed Sponsors

lead

ZS Pharma, Inc.

INDUSTRY

NCT02107092 - Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia. | Biotech Hunter | Biotech Hunter